公开(公告)号：US20170360783A1

公开(公告)日：2017-12-21

申请号：US15693963

申请日：2017-09-01

Applicant: AbbVie Inc.

Inventor： Christine Collins ,  Emily O. Dumas ,  Bo Fu ,  Abhishek Gulati ,  Yiran Bonnie Hu ,  Jens Kort ,  Matthew Kosloski ,  Preethi Krishnan ,  Yang Lei ,  Chih-Wei Lin ,  Ran Liu ,  Federico Mensa ,  Iok Chan Ng ,  Tami Pilot-Matias ,  David Pugatch ,  Susan Rhee ,  Nancy S. Shulman ,  Roger Trinh ,  Rolado M. Viani ,  Stanley Wang ,  Zhenzhen Zhang

IPC: A61K31/4985 ,  A61K31/454

CPC classification number: A61K31/4985 ,  A61K31/454 ,  A61K31/498 ,  A61K31/7072 ,  A61K2300/00

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 16 weeks, alternatively no more than 12 weeks, or alternatively no more than 8 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 16, 12, or 8 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20170333428A1

公开(公告)日：2017-11-23

申请号：US15667212

申请日：2017-08-02

Applicant: AbbVie Inc.

Inventor： Christine Collins ,  Bo Fu ,  Abhishek Gulati ,  Jens Kort ,  Matthew Kosloski ,  Yang Lei ,  Chih-Wei Lin ,  Ran Liu ,  Federico Mensa ,  Iok Chan Ng ,  Tami Pilot-Matias ,  David Pugatch ,  Nancy S. Shulman ,  Rogert Trinh ,  Rolando M. Viani ,  Stanley Wang ,  Zhenzhen Zhang

IPC: A61K31/4985 ,  A61K31/454

CPC classification number: A61K31/4985 ,  A61K31/454 ,  A61K31/498 ,  A61K31/7072 ,  A61K2300/00

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240082245A1

公开(公告)日：2024-03-14

申请号：US18386725

申请日：2023-11-03

Applicant: AbbVie Inc.

Inventor： Christine Collins ,  Bo Fu ,  Abhishek Gulati ,  Jens Kort ,  Matthew Kosloski ,  Yang Lei ,  Chih-Wei Lin ,  Ran Liu ,  Federico Mensa ,  Iok Chan NG ,  Tami Pilot-Matias ,  David Pugatch ,  Nancy S. Shulman ,  Roger Trinh ,  Rolando M. Viani ,  Stanley Wang ,  Zhenzhen Zhang

IPC: A61K31/4985 ,  A61K31/454 ,  A61K31/498 ,  A61K31/7072

CPC classification number: A61K31/4985 ,  A61K31/454 ,  A61K31/498 ,  A61K31/7072

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20200368229A9

公开(公告)日：2020-11-26

申请号：US15667212

申请日：2017-08-02

Applicant: AbbVie Inc.

Inventor： Christine Collins ,  Bo Fu ,  Abhishek Gulati ,  Jens Kort ,  Matthew Kosloski ,  Yang Lei ,  Chih-Wei Lin ,  Ran Liu ,  Federico Mensa ,  Iok Chan Ng ,  Tami Pilot-Matias ,  David Pugatch ,  Nancy S. Shulman ,  Roger Trinh ,  Rolando M. Viani ,  Stanley Wang ,  Zhenzhen Zhang

IPC: A61K31/4985 ,  A61K31/454

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20200330460A1

公开(公告)日：2020-10-22

申请号：US16643069

申请日：2018-08-30

Applicant: AbbVie Inc.

Inventor： Christine Collins ,  Emily O. Dumas ,  Bo Fu ,  Abhishek Gulati ,  Yiran Bonnie Hu ,  Jens Kort ,  Matthew Kosloski ,  Preethi Krishnan ,  Yang Lei ,  Chih-Wei Lin ,  Ran Liu ,  Frederico Mensa ,  Iok Chan Ng ,  Tami Pilot-Matias ,  David Pugatch ,  Susan Rhee ,  Nancy S. Shulman ,  Roger Trinh ,  Rolando M. Viani ,  Stanley Wang ,  Zhenzhan Zhang

IPC: A61K31/4985 ,  A61K31/454 ,  A61K31/7072 ,  A61K31/498

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20200222397A1

公开(公告)日：2020-07-16

申请号：US16635813

申请日：2018-07-20

Applicant: AbbVie Inc.

Inventor： Christine Collins ,  Bo Fu ,  Abhishek Gulati ,  Jens Kort ,  Matthew Kosloski ,  Yang Lei ,  Chih-Wei Lin ,  Ran Liu ,  Federico Mensa ,  Iok Chan Ng ,  Tami Pilot-Matias ,  David Pugatch ,  Nancy S. Shulman ,  Roger Trinh ,  Rolando M. Viani ,  Stanley Wang ,  Zhenzhen Zhang

IPC: A61K31/4985 ,  A61K31/454 ,  A61K31/7072 ,  A61K31/498

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 16 weeks, alternatively no more than 12 weeks, or alternatively no more than 8 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 16, 12, or 8 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.